APOGEarnings•globenewswire•
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Sentiment:Positive (70)
Summary
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire